Patents by Inventor Michele J. Losman

Michele J. Losman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated nucleic acid encoding an anti-IGF-1R antibody
    Patent number: 10377829
    Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: August 13, 2019
    Assignee: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
  • METHODS OF TREATING CANCER WITH ANTIBODIES THAT TARGET THE INSULIN-LIKE GROWTH FACTOR TYPE I RECEPTOR (IGF-1R)
    Publication number: 20170320952
    Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
    Type: Application
    Filed: July 11, 2017
    Publication date: November 9, 2017
    Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
  • Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
    Patent number: 9751948
    Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: September 5, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
  • METHODS OF TREATING CANCER WITH ANTIBODIES THAT TARGET THE INSULIN-LIKE GROWTH FACTOR TYPE I RECEPTOR (IGF-1R)
    Publication number: 20160333098
    Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
    Type: Application
    Filed: August 1, 2016
    Publication date: November 17, 2016
    Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
  • Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
    Patent number: 9441043
    Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: September 13, 2016
    Assignee: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
  • Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
    Publication number: 20150183880
    Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 2, 2015
    Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
  • Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
    Publication number: 20140086830
    Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
    Type: Application
    Filed: October 23, 2013
    Publication date: March 27, 2014
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
  • Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
    Publication number: 20100226884
    Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.
    Type: Application
    Filed: March 12, 2010
    Publication date: September 9, 2010
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
  • Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
    Patent number: 7413736
    Abstract: A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: August 19, 2008
    Assignee: Immunomedics, Inc.
    Inventors: Shui-on Leung, Michele J. Losman, Hans Hansen
  • Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
    Patent number: 7348419
    Abstract: A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: March 25, 2008
    Assignee: Immunomedics, Inc.
    Inventors: Shui-on Leung, Michele J. Losman, Hans Hansen
  • Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
    Patent number: 6730300
    Abstract: A humanized form of an anti-idotype antibody to CEA, e.g., hW12, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idotype also can be used as an immunogenic vaccine.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: May 4, 2004
    Assignee: Immunomedics, Inc.
    Inventors: Shui-on Leung, Michele J. Losman, Hans Hansen
  • HUMANIZATION OF AN ANTI-CARCINOEMBRYONIC ANTIGEN ANTI-IDIOTYPE ANTIBODY AND USE AS A TUMOR VACCINE AND FOR TARGETING APPLICATIONS
    Publication number: 20030054003
    Abstract: A humanized form of an antiidiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of antiCEA antibodies are maximized by using the humanized antiidiotype as a clearing agent for antiCEA antibodies or antibody fragments. The humanized antiidiotype also can be used as an immunogenic vaccine.
    Type: Application
    Filed: November 17, 1998
    Publication date: March 20, 2003
    Inventors: SHUI-ON LEUNG, MICHELE J. LOSMAN, HANS HANSEN